Treatment of hepatitis C in potential lung transplant candidates

Transplantation

Volumn 83, Issue 12, 2007, Pages 1652-1655

  Doucette, Karen E ^a,b   Weinkauf, Justin ^a   Sumner, Suzanne ^a   Ens, Karen ^a   Lien, Dale ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF ALBERTA HOSPITAL   (Canada)

Author keywords

Antiviral therapy; Hepatitis C; Interferon; Lung transplant

Indexed keywords

ALPHA2B INTERFERON; ANTIBIOTIC AGENT; CYCLOSPORIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PEGINTERFERON ALPHA2B; PREDNISONE; RIBAVIRIN; THYMOCYTE ANTIBODY;

ADULT; ADVERSE OUTCOME; ANXIETY DISORDER; ARTICLE; CLINICAL ARTICLE; DRUG WITHDRAWAL; FEMALE; HEPATITIS C; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER BIOPSY; LUNG DISEASE; LUNG GRAFT REJECTION; LUNG TRANSPLANTATION; MALE; OUTCOME ASSESSMENT; PATIENT SAFETY; PRIORITY JOURNAL; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; VIROLOGY;

ADULT; ANTIVIRAL AGENTS; FEMALE; FORCED EXPIRATORY VOLUME; GENOTYPE; HEMATOCRIT; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERON ALFA-2B; LEUKOCYTE COUNT; LIVER; LUNG TRANSPLANTATION; MALE; MIDDLE AGED; OXYGEN CONSUMPTION;

EID: 34250863837     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000264561.18380.22     Document Type: Article

References (20)

1. Hepatitis C. global prevalence. World Health Organization, Weekly Epidemiol Rec 1997; 72: 341.
2. Hoofnagle JH. Hepatitis C: The clinical spectrum of disease. Hepatology 1997; 26 (3 Suppl 1): 15S.
3. Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002; 122: 889.
4. Mathurin P, Mouquet C, Poynard T, et al. Impact of hepatitis B and C virus on kidney transplantation outcome. Hepatology 1999; 29: 257.
5. International guidelines for the selection of lung transplant candidates. The American Society for Transplant Physicians (ASTP)/American Thoracic Society (ATS)/European Respiratory Society (ERS)/International Society for Heart and Lung Transplantation (ISHLT). Am J Respir Crit Care Med 1998; 158: 335.
6. Cotler SJ, Jensen DM, Kesten S. Hepatitis C virus infection and lung transplantation: A survey of practices. J Heart Lung Transplant 1999; 18: 456.
7. Chan SE, Schwartz JM, Rosen HR. Treatment of hepatitis C in solid organ transplantation. Drugs 2004; 64: 489.
8. Gane E, Pilmore H. Management of chronic viral hepatitis before and after renal transplantation. Transplantation 2002; 74: 427.
9. Kasiske BL, Cangro CB, Hariharan S, et al. The evaluation of renal transplantation candidates: Clinical practice guidelines. Am J Transplant 2001; 1 Suppl 2: 3.
10. Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004; 39: 1147.
11. Arnett EN, Battle WE, Russo JV, Roberts WC. Intravenous injection of talc-containing drugs intended for oral use. A cause of pulmonary granulomatosis and pulmonary hypertension. Am J Med 1976; 60: 711.
12. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group. Hepatology 1994; 20: 15.
13. Desmond CP, Roberts SK, Dudley F, et al. Sustained virological response rates and durability of the response to interferon-based therapies in hepatitis C patients treated in the clinical setting. J Viral Hepat 2006; 13: 311.
14. Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003; 38: 645.
15. Kamar N, Rostaing L, Selves J, et al. Natural history of hepatitis C virus-related liver fibrosis after renal transplantation. Am J Transplant 2005; 5: 1704.
16. Alric L, Di-Martino V, Selves J, et al. Long-term impact of renal transplantation on liver fibrosis during hepatitis C virus infection. Gastroenterology 2002; 123: 1494.
17. Gonzalez-Roncero F, Gentil MA, Valdivia MA, et al. Outcome of kidney transplant in chronic hepatitis C virus patients: Effect of pretransplantation interferon-alpha2b monotherapy. Transplant Proc 2003; 35: 1745.
18. Hadziyannis SJ, Sette H, Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346.
19. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975.
20. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 2001; 358: 958.